Drug Patents owned by Vertex Pharms Inc

1. Drug name - KALYDECO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

CN102652128A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Mar, 2015

(7 years ago)

CN101935301A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN107501099A VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN101891680A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN104788328B VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN104788328A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101935301B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765B VERTEX PHARMS INC Atp-Binding Cassette Transport Proteins Regulating Agent
Jun, 2025

(2 years from now)

CN107501099B VERTEX PHARMS INC Modulator Of Atp-Binding Cassette Transport Protein
Jun, 2025

(2 years from now)

CN101006076B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101006076A VERTEX PHARMS INC Regulator Of Atp-Abc Transport Protein
Jun, 2025

(2 years from now)

CN101891680B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101384172B VERTEX PHARMS INC N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

IN282654B VERTEX PHARMS INC Modulators Of Atpbinding Cassette Transporters
Jun, 2025

(2 years from now)

EP1773816A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP1773816B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP2489659B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787A1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A3 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787B1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP1993360A2 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jul, 2026

(3 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

US10272046 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Feb, 2033

(10 years from now)

US8883206 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Feb, 2033

(10 years from now)

Drugs and Companies using IVACAFTOR ingredient

Treatment: Treatment of a moderate mild clinical phenotype of cf using ivacaftor in a patient age 6 months to <6 years who has one cftr mutation repsonsive to ivacaftor based on clinical and/or in vitro assay data; use of ivacaftor for treating cystic fibrosis in a patient with a mild to moderate cf phenotype with at least one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; treatment of a moderate to mild clinical phenotype of cf using ivacaftor in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data; Method of treating cystic fibrosis; treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has a r117h mutation in the cftr gene; method of treating a patient having cystic fibrosis, the patient having a r117h mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has a r117h mutation in the cftr gene; Method of treating cystic fibrosis; treatment of cf in a patient age 6 months to < 6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor; treatment of cf in a patient age 4 months to <6 years who has one cftr mutation responsive to ivacaftor based on clinical and/or in vitro assay data using a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor; Method of treating a patient having cystic fibrosis, such as a patient having a g551d mutation in cftr, using n-(5-hydroxy-2,4-di-tert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide; method of treating cystic fibrosis; treatment of cystic fibrosis using ivacaftor in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; treatment of cystic fibrosis using ivacaftor in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data; Treatment of cf in a patient age 6 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046; treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 10272046

Dosage: GRANULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG/PACKET GRANULE;ORAL Prescription
50MG/PACKET GRANULE;ORAL Prescription
75MG/PACKET GRANULE;ORAL Prescription

2. Drug name - ORKAMBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US10597384 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
Dec, 2028

(6 years from now)

US8507534 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
Sep, 2030

(7 years from now)

CN102652128A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Mar, 2015

(7 years ago)

CN107501099A VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN104788328B VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN101935301B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765B VERTEX PHARMS INC Atp-Binding Cassette Transport Proteins Regulating Agent
Jun, 2025

(2 years from now)

CN107501099B VERTEX PHARMS INC Modulator Of Atp-Binding Cassette Transport Protein
Jun, 2025

(2 years from now)

CN101006076B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101935301A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101891680B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101891680A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN104788328A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101006076A VERTEX PHARMS INC Regulator Of Atp-Abc Transport Protein
Jun, 2025

(2 years from now)

CN101384172A VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

CN101384172B VERTEX PHARMS INC N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101910156B VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

CN101910156A VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

CN103626744B VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

CN103626744A VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3] Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

IN282654B VERTEX PHARMS INC Modulators Of Atpbinding Cassette Transporters
Jun, 2025

(2 years from now)

EP1773816A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP1773816B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP2489659B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787A1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A3 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787B1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP1993360A2 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP2225230B1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP2225230A1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP3170818B1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

EP3170818A1 VERTEX PHARMS INC Solid Forms Of 3-(6-(1-(2,2-Difluorobenzo[D][1,3]Dioxol-5-Yl) Cyclopropanecarboxamido)-3-Methylpyridin-2-Yl) Benzoic Acid
Dec, 2028

(6 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7973038 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2026

(4 years from now)

US8741933 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2026

(4 years from now)

US9216969 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2026

(4 years from now)

US9931334 VERTEX PHARMS INC Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

US8846718 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxo1-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid Dec, 2028

(6 years from now)

US8653103 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Dec, 2028

(6 years from now)

US9150552 VERTEX PHARMS INC Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid Dec, 2028

(6 years from now)

US11052075 VERTEX PHARMS INC Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof Dec, 2028

(6 years from now)

US10076513 VERTEX PHARMS INC Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and administration thereof Dec, 2028

(6 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

US9192606 VERTEX PHARMS INC Dosage units of 3-(6-(1-(2,2-difluorobenzo[d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Sep, 2029

(7 years from now)

US8716338 VERTEX PHARMS INC Dosage units of 3-(6-(1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid Sep, 2030

(7 years from now)

US8993600 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Dec, 2030

(8 years from now)

Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient

Treatment: Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and ivacaftor; Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using ivacaftor and lumacaftor; method of treating cystic fibrosis in patients who are homozygous for the f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene; Method of treating cystic fibrosis in a patient age 6 or older homozygous for the f508del mutation in the cftr gene using lumacaftor and a solid composition comprising amorphous (less than about 30% crystalline) ivacaftor; Method of treating a patient having cystic fibrosis using ivacaftor and lumacaftor; Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor form i and ivacaftor; Treatment of cystic fibrosis in patients 6 years and older who are homozygous for the f508del mutation in the cftr gene using the tablet according to claim 1 of u.s. patent no. 11,052,075, where the tablet further comprises ivacaftor; Treatment of cystic fibrosis in a patient age 12 years or older who is homozygous for the f508del mutation in the cftr gene using the tablet comprising lumacaftor as recited in claim 1, 19, or 21 of u.s. patent no. 10,076,513 and ivacaftor; Method of treating cystic fibrosis in a patient, the patient having the f508del mutation in cftr, using a dosage unit as defined in claim 1 of u.s. patent no. 9,192,606; Treatment of cystic fibrosis in a patient age 2-5 years who is homozygous for the f508del mutation in the cftr gene using the dosage unit comprising lumacaftor as recited in claim 1 of us patent 8716338 and ivacaftor

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
125MG;100MG TABLET;ORAL Prescription
125MG;200MG TABLET;ORAL Prescription

3. Drug name - SYMDEKO (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

US10239867 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(4 years from now)

US7645789 VERTEX PHARMS INC Indole derivatives as CFTR modulators
May, 2027

(4 years from now)

US8623905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US7776905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2027

(4 years from now)

CN101460489A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Aug, 2013

(9 years ago)

CN102652128A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Mar, 2015

(7 years ago)

CN101935301A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN107501099A VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN101891680A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN104788328B VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN104788328A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101935301B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765B VERTEX PHARMS INC Atp-Binding Cassette Transport Proteins Regulating Agent
Jun, 2025

(2 years from now)

CN107501099B VERTEX PHARMS INC Modulator Of Atp-Binding Cassette Transport Protein
Jun, 2025

(2 years from now)

CN101006076B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101006076A VERTEX PHARMS INC Regulator Of Atp-Abc Transport Protein
Jun, 2025

(2 years from now)

CN101891680B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101384172B VERTEX PHARMS INC N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

IN282654B VERTEX PHARMS INC Modulators Of Atpbinding Cassette Transporters
Jun, 2025

(2 years from now)

IN200804446P2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

IN272379B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP1773816B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP1773816A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP2502911A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787B1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787A1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A3 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP1993360A2 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP2007756B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP2674428B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP2007756A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP3327016A1 VERTEX PHARMS INC Preparation Of Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP2674428A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP3327016B1 VERTEX PHARMS INC Preparation Of Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP3091011B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP3091011A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jul, 2026

(3 years from now)

US9931334 VERTEX PHARMS INC Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9974781 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Apr, 2027

(4 years from now)

US10022352 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Apr, 2027

(4 years from now)

US8598181 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters May, 2027

(4 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

US8415387 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2027

(5 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

US10081621 VERTEX PHARMS INC Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide Mar, 2031

(8 years from now)

US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof Jul, 2033

(10 years from now)

US10058546 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxo1-5-y1)-N-(1-(2,3-dihydroxypropy1)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-y1)-1H-indol-5-y1) cyclopropanecarbox-amide and administration thereof Jul, 2033

(10 years from now)

US10206877 VERTEX PHARMS INC Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases Apr, 2035

(12 years from now)

Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient

Treatment: Tezacaftor and ivacaftor for the treatment of patients with a mild to moderate clinical phenotype of cystic fibrosis having at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence; Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients age 6 years and older who have a r117h mutation in the cftr gene; Treating cystic fibrosis patients ages 6 and older, who are homozygous for f508del or have at least 1 cftr gene mutation responsive to tezacaftor/ivacaftor, with tezacaftor and a solid composition comprising amorphous (<30% crystalline) ivacaftor; treating cystic fibrosis patients ages 12 and older, who are homozygous for f508del or have at least 1 cftr gene mutation responsive to tezacaftor/ivacaftor, with tezacaftor and a solid composition comprising amorphous (<30% crystalline) ivacaftor; Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the f508del mutation or having at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence; Treatment of cystic fibrosis in patients aged 12 and older, who are homozygous for the f508del mutation or have at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor, with tezacaftor and ivacaftor; treatment of cystic fibrosis in patients aged 6 and older, who are homozygous for the f508del mutation or have at least one cftr gene mutation that is responsive to tezacaftor/ivacaftor, with tezacaftor and ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older, who are homozygous for the f508del mutation or heterozygous for f508del and a second cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with tezacaftor and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older, who are homozygous for the f508del mutation or heterozygous for f508del and a second cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with tezacaftor and ivacaftor; Treatment of cystic fibrosis in patients age 12 and older, who have two copies of the f508del mutation or who have at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; treatment of cystic fibrosis in patients ages 6 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; treatment of cystic fibrosis in patients age 6 and older, who have two copies of the f508del mutation or who have at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; treatment of cystic fibrosis in patients ages 12 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,081,621; Tezacaftor and ivacaftor for the treatment of cystic fibrosis in patients who are homozygous for the f508del mutation or heterozygous for the f508del mutation and a second mutation that is responsive to tezacaftor/ivacaftor; Treatment of cystic fibrosis in patients 12 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->a, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s patent 10058546; treatment of cystic fibrosis in patients 6 years and older, with a f508del or g551d cftr gene mutation and a a455e, 2789+5g->, or 3849+10kbc->t mutation, comprising concurrent coadministration of the compositions of claim 1 of u.s. patent 10058546; treatment of cf in patients 6 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, and 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; treatment of cf in patients 12 years and older who have a f508del or g551d cftr mutation and a 2nd mutation selected from r117h, a455e, 2789+5g->a, & 3849+10kbc->t, comprising concurrent coadministration of the compositions of claim 1 of us 10058546; Treatment of cystic fibrosis in patients ages 12 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; treatment of cystic fibrosis in patients ages 6 and older, who have two copies of the f508del mutation or one f508del mutation and a cftr mutation predicted to be responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; treatment of cystic fibrosis in patients age 6 and older, who have two copies of the f508del mutation or at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877; treatment of cystic fibrosis in patients age 12 and older, who have two copies of the f508del mutation or at least one cftr mutation that is responsive to tezacaftor/ivacaftor, with the composition of claim 1 of us 10,206,877

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
75MG;75MG, 50MG TABLET;ORAL Prescription
150MG;150MG, 100MG TABLET;ORAL Prescription

4. Drug name - TRIKAFTA (COPACKAGED)

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8754224 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
Dec, 2026

(4 years from now)

US10239867 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Apr, 2027

(4 years from now)

US8623905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US7645789 VERTEX PHARMS INC Indole derivatives as CFTR modulators
May, 2027

(4 years from now)

US7495103 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
May, 2027

(4 years from now)

US7776905 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters
Jun, 2027

(4 years from now)

US10758534 VERTEX PHARMS INC NA
Oct, 2035

(13 years from now)

US10793547 VERTEX PHARMS INC Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Dec, 2037

(15 years from now)

CN101460489A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Aug, 2013

(9 years ago)

CN102652128A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Mar, 2015

(7 years ago)

CN101935301A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN107501099A VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN101891680A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN104788328B VERTEX PHARMS INC Atp-Binding Cassette Transport Protein Modulators
Jun, 2025

(2 years from now)

CN104788328A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765A VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101935301B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN103641765B VERTEX PHARMS INC Atp-Binding Cassette Transport Proteins Regulating Agent
Jun, 2025

(2 years from now)

CN107501099B VERTEX PHARMS INC Modulator Of Atp-Binding Cassette Transport Protein
Jun, 2025

(2 years from now)

CN101006076B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101006076A VERTEX PHARMS INC Regulator Of Atp-Abc Transport Protein
Jun, 2025

(2 years from now)

CN101891680B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

CN101384172B VERTEX PHARMS INC N - (2, 4 - (1, 1 - - Dimethyl Ethyl) -5 - Phenyl] -1, 4 - - Dihydro - -4--- Oxo-Quinoline -3 - Formamide In Solid Form
Dec, 2026

(4 years from now)

CN101384172A VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

CN107690281B VERTEX PHARMS INC Modulators Of Cystic Fibrosis Transmembrane Transduction Regulatory Factor
Oct, 2035

(13 years from now)

CN107690281A VERTEX PHARMS INC Cystic Fibrosis Transmembrane Transduction Regulatory Factor Regulator
Oct, 2035

(13 years from now)

IN282654B VERTEX PHARMS INC Modulators Of Atpbinding Cassette Transporters
Jun, 2025

(2 years from now)

IN200804446P2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

IN272379B VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP1773816B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP1773816A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jul, 2020

(2 years ago)

EP2502911A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787B1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP3216787A1 VERTEX PHARMS INC Intermediates For The Preparation Of Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2489659A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP2502911A3 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Jun, 2025

(2 years from now)

EP1993360A2 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705A1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360B1 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP1993360A4 VERTEX PHARMS INC Solid Forms Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP3219705B1 VERTEX PHARMS INC Pharmaceutical Compositions Of The Amorphous Form Of N-[2,4-Bis(1,1-Dimethylethyl)-5-Hydroxyphenyl]-1,4-Dihydro-4-Oxoquinoline-3-Carboxamide
Dec, 2026

(4 years from now)

EP2007756B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP2674428B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP2007756A2 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP3327016A1 VERTEX PHARMS INC Preparation Of Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP2674428A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP3327016B1 VERTEX PHARMS INC Preparation Of Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP3091011B1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP3091011A1 VERTEX PHARMS INC Modulators Of Atp-Binding Cassette Transporters
Apr, 2027

(4 years from now)

EP3203840A4 VERTEX PHARMS INC Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator
Oct, 2035

(13 years from now)

EP3203840B1 VERTEX PHARMS INC Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator
Oct, 2035

(13 years from now)

EP3203840A1 VERTEX PHARMS INC Modulators Of Cystic Fibrosis Transmembrane Conductance Regulator
Oct, 2035

(13 years from now)

EP3551622A1 VERTEX PHARMS INC Modulator Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods Of Treatment, And Process For Making The Modulator
Dec, 2037

(15 years from now)

EP3551622B1 VERTEX PHARMS INC Modulator Of Cystic Fibrosis Transmembrane Conductance Regulator, Pharmaceutical Compositions, Methods Of Treatment, And Process For Making The Modulator
Dec, 2037

(15 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8629162 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jun, 2025

(2 years from now)

US8354427 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Jul, 2026

(3 years from now)

US8410274 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9670163 VERTEX PHARMS INC Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US9931334 VERTEX PHARMS INC Solid forms of N[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide Dec, 2026

(4 years from now)

US10022352 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Apr, 2027

(4 years from now)

US9974781 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Apr, 2027

(4 years from now)

US8598181 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters May, 2027

(4 years from now)

US8324242 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Aug, 2027

(4 years from now)

US8415387 VERTEX PHARMS INC Modulators of ATP-binding cassette transporters Nov, 2027

(5 years from now)

US10646481 VERTEX PHARMS INC Pharmaceutical composition and administrations thereof Aug, 2029

(6 years from now)

US10081621 VERTEX PHARMS INC Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide Mar, 2031

(8 years from now)

US9012496 VERTEX PHARMS INC Pharmaceutical compositions of (R)-1-(2,2-difluorobenzo[D][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide and administration thereof Jul, 2033

(10 years from now)

US11179367 VERTEX PHARMS INC Pharmaceutical compositions for treating cystic fibrosis Dec, 2037

(15 years from now)

Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient

Treatment: Treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of a moderate to mild clinical phenotype of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elx, tez, and iva; treatment of a moderate to mild clinical phenotype of cf in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elx, tez, and iva; Treatment of cystic fibrosis in patients aged 12 years and older who have one f508del mutation and one r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older who have a r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have a r117h mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; Treatment of cf in patients aged 12 years and older who have at least one f508del mutation in the cftr gene using a solid composition comprising elexacaftor, tezacaftor, amorphous ivacaftor, and less than about 30% crystalline ivacaftor; treatment of cf in patients 12 years and older who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data using a solid composition comprising elx, tez, amorphous iva, and < ~30% crystalline iva; treatment of cf in patients 6 years and older who have at least one f508del mutation or a mutation in the cftr gene that is responsive based on in vitro data using a solid composition comprising elx, tez, amorphous iva, and < ~30% crystalline iva; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with an effective amount of a pharmaceutical composition comprising elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with an effective amount of a pharmaceutical composition comprising elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with elexacaftor, tezacaftor, and ivacaftor; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition according to claim 1 of us 10081621; treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a composition according to claim 1 of us 10081621; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene or a mutation in the cftr gene that is responsive based on in vitro data with a composition according to claim 1 of us 10081621; Treatment of cystic fibrosis in patients aged 12 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor; treatment of cystic fibrosis in patients aged 6 years and older who have at least one f508del mutation in the cftr gene with a composition comprising elexacaftor, tezacaftor, and ivacaftor; and another composition comprising ivacaftor; Treatment of cystic fibrosis in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data with a composition according to at least one of claims 1-9 of us11179367

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
50MG,37.5MG,25MG; 75MG TABLET;ORAL Prescription
100MG,75MG,50MG; 150MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.